e-mail

office.cidr@iisc.ac.in

Slide
Slide
Slide
Slide
previous arrow
next arrow

Viral Biosafety Level – 3 (Viral BSL-3) Laboratory

The Viral Biosafety level three facility (BSL-3) has been established in the Centre for Infectious Disease Research (CIDR) Building, IISc Campus, Bangalore for conducting research on BSL3 category viral pathogens such as SARS-CoV-2. It consists of one BSL3 lab for cell-based experiments and one infection-cum-necropsy room for animal experiments. There are appropriate change rooms, an autoclave room, and a plant room. This lab has special safety and engineering features for maintaining requisite negative pressure environment to ensure unidirectional airflow, and for ensuring safety of lab personnel. Go through the SOPs to understand the prerequisites for accessing the facility.

We undertake consultancy research projects​ related to vaccine or anti-viral studies. For further details contact at shashankt@iisc.ac.in

SL No.​

Company​

Aim of the study​

1​

GLYCOVAX PHARMA, CANADA​

Evaluating efficacy of a glycoconjugate vaccine candidate against SARS-CoV-2 ​

2​

GENNOVA BIOPHARMACEUTICALS LTD., INDIA ​

Evaluating efficacy of a mRNA based Covid-19 vaccine candidate  (GEMCOVAC-19)​

3​

PREMAS BIOTECH PVT LTD., INDIA​

Evaluating efficacy of a Virus like particle vaccine candidate against SARS-CoV-2​

4​

CSIR-IMTECH, INDIA​

To test efficacy of a subunit vaccine against SARS-CoV-2 virus​

5​

CSIR-CCMB​

Evaluating efficacy of a mRNA based Covid-19 vaccine candidate​

6​

BARC, INDIA​

Evaluating efficacy of a Liposomal Spike vaccine candidate against SARS-CoV-2​

​

ANTIVIRAL STUDIES​

SL No.​

Company​

Aim of the study​

1​

GENEXT GENOMICS PVT LTD​

Evaluating efficacy of an anti-SARS-CoV-2 ScFVs in Spike pseudotyped entry assay​

2​

BIOMONETA RESEARCH PVT. LTD., INDIA​

Evaluating efficacy of ZeBox in eliminating airborne influenza and SARS-CoV-2 viruses.​

3​

KASHIV BIOSCIENCES, USA​

To test in vitro antiviral efficacy of new synthetic chemical entities against SARS-CoV-2 in cell culture system​

4​

SHARP BUSINESS SYSTEMS, INDIA​

To test for the in vitro anti SARS-CoV-2 activity of TUNGSTEN TRIOXIDE-COATED PLATES  and NATURIZER (disinfectant) solution​

5​

CSIR-CIMAP, INDIA​

To test the anti-SARS-CoV-2 activity of different herbal formulations through oral administration.

SERVICES PROVIDED​

Vaccine testing in animal model and the antiviral studies in cell culture.​

  • RT-PCR: SARS-CoV-2 Viral load (Lungs, nasal turbinates, nasal wash etc.) , Pro and anti-inflammatory cytokines level.​
  • ELISA: SARS-CoV-2 RBD specific antibodies, cytokines level.​
  • Histology: Lungs, spleen, liver, nasal turbinates etc.​
  • Neutralization assays: Live virus and Psuedovirus based assays​
  • Other parameters studies: Body weight, clinical signs, organ’s gross morphology.​
  • Cytotoxicity and antiviral assays: In VERO and HEK 293T cells etc.​

SARS-CoV-2 virus variants available for studies:
Wuhan, Alpha, Beta, Gamma, Delta, Omicron.

NEWS​​

  1. Japan’s Sharp Naturizer sanitizer solution proves effectiveness against COVID-19 (biospectrumasia.com)
  2. Sharp Workspace Procat Photocatalyst found effective against SARS- CoV-2 (aninews.in)
  3. Biomoneta’s ZeBox effective against airborne SARS-CoV-2 (biospectrumindia.com)
  4. DCGI approves indigenous mRNA Covid jab for emergency use in adults: Report | Business Standard News (business-standard.com)

Dr. Shashank Tripathi
Faculty Incharge
VIRAL Biosafety Level-3 Laboratory
Centre for Infectious Disease Research (CIDR)
MCB Department
Indian Institute of Science
CV Raman Avenue
Bangalore-560012
India
080-2292884/3063

Dr. Rohan Narayan
Incharge
VIRAL Biosafety Level-3 Laboratory
Centre for Infectious Disease Research (CIDR)
Indian Institute of Science
CV Raman Avenue
Bangalore-560012
India
080-2292884/3063